Shares of Danish CNS specialist Lundbeck closed down 6.9% at 184.45 kroner yesterday as it posted financials for the first half of 2021. 19 August 2021
Otsuka Pharmaceutical yesterday announced top-line outcomes from a Phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD), that did not meet the primary endpoint, change from baseline in the Zanarini Rating Scale for BPD. 19 August 2021
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found. 18 August 2021
US pharma major Eli Lilly has announced executive leadership changes and the creation of neuroscience and immunology business units. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. 18 August 2021
The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent 17 August 2021
As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leading scientists in the field - much of which will point the way for potential therapeutic breakthroughs. 13 August 2021
The US Department of Veterans Affairs (VA) has snubbed Biogen and Eisai’s Aduhelm (aducanumab-avwa) by excluding it from its national formulary. 13 August 2021
The US Food and Drug Administration on Thursday approved a new indication for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for idiopathic hypersomnia (IH) in adults. 13 August 2021
Central nervous system (CNS) specialist Axsome Therapeutics will hope a positive report from GlobalData could take the sting out of a recent run of bad news. 12 August 2021
German CNS specialist atai Life Sciences has announced the launch of Revixia Life Sciences, a wholly-owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders. 12 August 2021
Japanese drugmaker Chugai says it has launched Evrysdi (risdiplam) Dry Syrup 60mg for the treatment of spinal muscular atrophy (SMA). Evrysdi had been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) on June 23, 2021, and was listed on the national health insurance (NIH) reimbursement price list this week. 12 August 2021
The Parkinson’s disease (PD) market is expected to almost triple in sales in the seven major markets (7MM: The USA, France, Germany, Spain, Italy, the UK, and Japan) by 2029, rising from $4 billion in 2021 to $11.5 billion in 2029 at an impressive 12.6% compound annual growth rate (CAGR). 11 August 2021
UK-based drug discovery and development company Mission Therapeutics and US pharma major AbbVie today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration. 9 August 2021
The USA’s Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (trade name Aduhelm) for the treatment of Alzheimer’s disease. 7 August 2021
The UK Competition and Markets Authority (CMA) has provisionally found that US pharma giant Pfizer and its UK distributor Flynn Pharma, abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case. 6 August 2021
The US Food and Drug Administration’s recent approval of Aduhelm (aducanumab) to treat patients with Alzheimer's disease using the accelerated approval pathway has been questioned and now this is to be investigated by the Office of the Inspector General at the Department of Health and Human Services. 5 August 2021
A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumor is to launch at 15 National Health Service (NHS) hospitals, following promising results from a Phase I study in 27 patients. 4 August 2021
US drugmaker Eli Lilly saw its revenue rise by 23% in the second quarter of 2021, which amounts to a 12% jump when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. 3 August 2021
Finnish drugmaker Orion Corp has entered into an agreement to distribute US biopharma firm Marinus Pharmaceuticals’ CNS-selective GABAA modulator, ganaxolone, as a treatment for orphan, genetic disorders ganaxolone, across Europe. 3 August 2021
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Recursion (Nasdaq: RXRX) has seen its shares fall by more than 15% following the announcement of Phase II trial results for REC-994, an investigational treatment for symptomatic cerebral cavernous malformation (CCM). 4 September 2024